IL2 and graft versus host disease: In human clinical studies, low dose of IL-2 (LDIL-2) has been used in small cohorts of patients with systemic lupus erythematosus (SLE), chronic graft versus host disease (GVHD), Type 1 diabetes (T1D), and Hepatitis C virus (HCV) related vasculitis.